Neuroreport · 1997 · 88 citations · 11 references
Life SciencesNeurosciencePharmacologyNeurochemistryNeurodegenerationNeuropharmacologyAlzheimer DiseaseNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionNicotine PharmacologyTobacco UseAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid-beta-induced NeurotoxicityCholinergic NeuroprotectionNeurotoxic ActionNicotine Receptor PharmacologyNicotinic AntagonistsNicotinic Receptor Pharmacology
Two major features of Alzheimer's disease (AD) are beta-amyloid protein (beta AP) deposition and a severe cholinergic deficit. An association between the two is suggested by the negative correlation found between cigarette smoking and AD. We sought to investigate this further by examining the effects of acute and chronic nicotine exposure on beta AP-induced neuronal loss in rat hippocampal cultures. Nicotine was found to attenuate the neurotoxicity of higher concentrations of beta AP(25-35), an effect which was enhanced by longer nicotine pretreatment and significantly inhibited by the nicotine receptor antagonist mecamylamine. Our results suggest that nicotine partially protects against the neurotoxic actions of beta AP(25-35) via a receptor-mediated pathway.
11
Manickavasagom Alkondon, Edson X. Albuquerque · Journal of Pharmacology and Experimental Therapeutics · 1993 · 553 citations
Relation between nicotine intake and Alzheimer's disease.
Cornelia M. van Duijn, Albert Hofman · BMJ · 1991 · 201 citations · Full text